

1 **ORIGINAL ARTICLE**

2

3 **High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease;**
4 **metabolic and clinical predictors identified by machine learning**

5

6 **TITLE PAGE**

7

8 **Author List:**

9 Martin McDonnell^{1§}, Richard J Harris^{1§}, Florina Borca^{1,2}, Tilly Mills¹, Louise Downey¹, Suranga Dharmasiri¹,
10 Mayank Patel³, Benjamin Zaré¹, Matt Stammers^{1,2}, Trevor R Smith¹, Richard Felwick¹, JR Fraser Cummings^{1,4},
11 Hang T.T. Phan², Markus Gwiggner¹

12 ¹ Department of Gastroenterology, University Hospital Southampton, Southampton, United Kingdom

13 ² University of Southampton NIHR Biomedical Research Facility, Southampton, United Kingdom

14 ³ Department of Diabetes and Endocrinology, University Hospital Southampton, Southampton, United Kingdom

15 ⁴ Faculty of Medicine, University of Southampton, Southampton, United Kingdom

16 [§] Joint first authors

17

18 **Corresponding Author:**

19

20 Dr Martin McDonnell

21 Department of Gastroenterology

22 Mail point 190

23 University Hospital Southampton

24 Tremona Road

25 Southampton

26 SO16 6YD

27

28 m.j.mcdonnell@soton.ac.uk

29

30

31 **ABSTRACT**

32

33 **Background**

34 Glucocorticosteroids (GC) are long-established, widely used agents for induction of remission in inflammatory
35 bowel disease (IBD). Hyperglycaemia is a known complication of GC treatment with implications for morbidity and
36 mortality. Published data on prevalence and risk factors for GC-induced hyperglycaemia in the IBD population are
37 limited. We prospectively characterise this complication in our cohort, employing machine-learning methods to
38 identify key predictors of risk.

39

40 **Methods**

41 We conducted a prospective observational study of IBD patients receiving intravenous hydrocortisone (IVH).
42 Electronically triggered three times daily capillary blood glucose (CBG) monitoring was recorded alongside diabetes
43 mellitus (DM) history, IBD biomarkers, nutritional and IBD clinical activity scores. Hyperglycaemia was defined as
44 $CBG \geq 11.1$ mmol/L and undiagnosed DM as $HbA1c \geq 48$ mmol/mol. Random Forest regression models were used to
45 extract predictor-patterns present within the dataset.

46

47 **Findings**

48 94 consecutive IBD patients treated with IVH were included. 60% (56/94) of the cohort recorded an episode of
49 hyperglycaemia, including 57% (50/88) of those with no prior history of DM, of which 19% (17/88) and 5% (4/88)
50 recorded a $CBG \geq 14$ mmol/L and ≥ 20 mmol/L, respectively. The Random Forest models identified increased CRP
51 followed by a longer IBD duration as leading risk predictors for significant hyperglycaemia.

52

53 **Interpretation**

54 Hyperglycaemia is common in IBD patients treated with intravenous GC, therefore CBG monitoring should be
55 included in routine clinical practice. Machine learning methods can identify key risk factors for clinical
56 complications. Physicians should consider steroid-sparing strategies in high-risk patients such as those with high
57 admission CRP or a longer IBD duration. There is an emergent case for research to explore steroid-free treatment
58 regimens for hospitalised patients with severe IBD flares.

59

60 **Funding**

61 No specific funding was received for this study.

62 **Evidence before this study**

63 Glucocorticosteroids (GC) are long-established induction agents in the management of inflammatory bowel disease
64 (IBD). They are recommended first-line therapy in consensus guidelines and prescribing remains widespread, with
65 an estimated 30% of IBD patients exposed annually. Hyperglycaemia is a known complication of GC and has been
66 linked to increased length of hospital stay, morbidity and mortality. Small case series of GC treated medical patients
67 suggest a higher risk of hyperglycaemia in the hospitalised population but have suffered from a lack of systematic
68 blood glucose monitoring.

69
70 **Added value of this study**

71 This is the first study utilising prospective, systematic monitoring of capillary blood glucose (CBG) to determine the
72 frequency of hyperglycaemia in a GC-treated hospitalised IBD population. We report that more than half of IBD
73 patients without prior diabetes mellitus treated with intravenous hydrocortisone (IVH), will develop hyperglycaemia
74 (CBG ≥ 11.1 mmol/L). Random Forest regressors pinpointed CRP and IBD duration as the strongest predictor of this
75 adverse outcome.

76
77 **Implications of all the available evidence**

78 Hyperglycaemia is a common complication of IVH therapy in hospitalised IBD patients, particularly in those with
79 high inflammatory burden. The monitoring and management of this complication, which has potential implications
80 for the morbidity, mortality and subsequent risk of diabetes diagnosis should become part of routine clinical
81 practice.

82
83
84 **Contribution statement:**

85 MM, RJH, SD and MG were responsible for the original concept and planning of the study. MM, RJH, TM, SD, BZ
86 and LD were responsible for clinical data collection and analysis. FB and HP were responsible for data extraction,
87 analysis and modelling. RJH and MM contributed equally to this work and drafted the manuscript, which RF, TS,
88 MP, JRFC, HP, MS and MG critically reviewed and revised.

89
90
91
92
93

94 **INTRODUCTION**

95
96 In the 1950's Truelove and Witts performed the first randomised controlled trial of glucocorticosteroids (GC) in
97 active ulcerative colitis (UC), demonstrating a reduction in mortality from 10.9% to 4.6% after two months of
98 treatment.¹ 70 years later, GC remain a common treatment for inflammatory bowel disease (IBD); a recent UK
99 multi-centre study identified 30% of patients were exposed to GC in the preceding 12 months.² GC are first-line
100 induction agents for moderate to severe Crohn's Disease (CD) and UC in consensus guidelines and intravenous GC
101 are widely used as the initial medical therapy for IBD patients admitted to hospital with severe disease flares.^{3,4}
102

103 The mechanism of action of GC is mediated via the cytosolic glucocorticoid receptor (cGR). After GC binding,
104 cGR-associated proteins dissociate, and the GC-cGR complex translocates to the nucleus. The nuclear GC-cGR
105 complex binds to DNA, upregulating the transcription of anti-inflammatory cytokines (e.g. IL-10, annexin 1) and
106 downregulating transcription of pro-inflammatory mediators (e.g. IL-1 α , IL-1 β , IL-8, TNF α). More rapid, non-
107 genomic, effects occur via both the cGR dissociated proteins and likely via other novel transmembrane receptors.⁵
108 Steroid-induced hyperglycaemia is mediated by decreased β -cell insulin production, increased insulin resistance and
109 increased gluconeogenesis.⁶
110

111 Studies in other GC-treated populations demonstrate both short and long-term severe adverse effects including
112 ocular, musculoskeletal, cardiovascular, metabolic and infectious complications.⁷ In addition, de-novo
113 hyperglycaemia and deterioration of glycaemic control in those with pre-existing diabetes mellitus (DM) have been
114 recognised adverse effects of GC since the 1950s.⁸ The specific risk in IBD hospitalised patients with severe IBD
115 flares, however, is not known.
116

117 Hyperglycaemia has been associated with increased length of stay, morbidity and mortality in non-critical care
118 medical and surgical patients.⁹ At least 67 cases of GC induced metabolic emergencies including ketoacidosis and
119 hyperosmolar hyperglycaemic states have been reported, 11 of which were fatal.¹⁰ Following 2 cases of GC-related
120 diabetic crisis at our institution in IBD patients with no prior diabetes, electronically triggered systematic capillary
121 blood glucose (CBG) monitoring was introduced for all prescribed intravenous hydrocortisone (IVH). This allowed
122 the systematic study of hyperglycaemia in hospitalised IBD patients receiving IVH.
123

124 **MATERIALS AND METHODS**

125
126 We conducted a prospective observational study of consecutive admissions of IBD patients treated with IVH
127 between October 2017 and December 2018. Included subjects had a confirmed diagnosis of IBD (either historic or
128 during admission episode) and received at least four doses of 100mg IVH over 24 hours.
129

130 Subjects had three times daily CBG monitoring automatically triggered by electronic prescription of IVH. CBG
131 results were automatically digitally captured in the electronic patient record. Predictor variables included admission
132 IBD severity score (Harvey Bradshaw Index or partial Mayo Score), serum biochemistry, HbA1c, faecal
133 calprotectin, C-reactive protein, potential DM risk factors (BMI, family history, concomitant medications), self-
134 reported weight loss and MUST (Malnutrition Universal Screening Tool) score.¹¹
135

136 Patients developing a CBG ≥ 14 mmol/l were referred to the diabetes team for consideration of treatment.
137 Undiagnosed DM was excluded by baseline HbA1c < 48 mmol/mol or a pre-IVH CBG < 11.1 mmol/L.¹² Biochemical
138 follow up was performed at one year to assess repeat HbA1c measurements and serum and faecal biomarker
139 assessments.
140

141 Laboratory values outside the quantification limit were substituted with the upper/lower limit value. Categorical and
142 continuous predictors were handled and formatted appropriately. Data were analysed using Python v3.7.4 and R

143 v3-6-1. Descriptive statistics were applied to cohorts, and Pearson correlations between independent and dependent
 144 variables were ascertained with matplotlib/seaborn heat-maps. Random Forest (RF) machine learning models using
 145 the scikit-learn package v0.22.1 were constructed to regress the phenotypic and admission clinical predictors.^{13,14}
 146 Pairwise correlations between input features (see supplementary data) were identified to eliminate similar features.
 147 Then multivariable RF models were constructed and optimised using random grid search. Subsequently 5-fold cross-
 148 validation with a train-test split was used to test effectiveness at predicting glucose levels in the internal holdout set.
 149 Mean squared error was the reported metric.

151 The protocol was reviewed and approved by the UK Health Research Authority - reference 19/HRA/0033.

153 RESULTS

155 Demographics

157 94 IBD inpatient episodes met the inclusion criteria; 54 for CD, 36 for UC and 4 for IBD-as yet unclassified
 158 (IBDU). The median length of IVH treatment was four days (range 1-11).

160 5/94 episodes were for patients with a prior diagnosis of Type 2 DM. One further subject had a pre-GC treatment
 161 CBG of 13.9mmol/L and was thus reclassified as undiagnosed Type 2 DM.

162

		CD	IBDU	UC
	n	54	4	36
Age		42.2 (37.9 - 46.5)	49.8 (28.4 - 71.1)	43.1 (37.0 - 49.2)
Gender	Female	25 (46.3)	2 (50.0)	19 (52.8)
BMI	<18.5	6 (11.1)	1 (25.0)	3 (8.3)
	18.5 - 25	28 (51.9)	2 (50)	16 (44.4)
	25-30	13 (24.1)	1 (25)	14 (38.9)
	>30	7 (13.0)	0 (0.0)	3 (8.3)
MUST Score	0	17 (31.5)	1 (25.0)	17 (48.6)
	1	13 (24.1)	1 (25.0)	10 (28.6)
	2	13 (24.1)	2 (50.0)	4 (11.4)
	≥3	11 (20.4)	0 (0.0)	4 (11.4)
Length of diagnosis (years)		7.3 (4.6 - 10.0)	3.3 (0 - 8.4)	5.0 (3.2 - 6.8)
History of Diabetes	No	49 (90.7)	4 (100.0)	35 (97.2)
	Type 2 DM	5 (9.3)	0 (0.0)	1 (2.8)
Admission HBA1C		38.5 (35.5 - 41.5)	37.0 (33.1 - 40.8)	37.7 (35.8 - 39.6)
Admission Calprotectin		2854 (1980 - 2298)	2491 (NA)	3159 (2302 - 4071)
Admission CRP		75.9 (50.5 - 101.3)	138.0 (106.7 - 169.3)	88.9 (53.6 - 124.1)
PMS		..	5.50 (4.5 - 6.5)	7.78 (7.2 - 8.3)
HBI		14.7 (13.0-16.5)
Current Treatment	Oral steroids	8 (14.8)	1 (25)	6 (16.7)
	Oral 5ASA	2 (3.7)	2 (50)	20 (55.6)
	Immunomodulator	18 (33.3)	0 (0)	6 (16.7)
	Anti-TNF	10 (19.2)	0 (0)	10 (29.4)
	Vedolizumab	2 (3.8)	0 (0)	0 (0.0)
	Ustekinumab	7 (13.5)	0 (0)	0 (0.0)
Smoking	Current	12 (23.5)	0 (0)	0 (0.0)
	Ex-smoker	9 (17.7)	1 (25.0)	13 (36.1)
	Never smoked	30 (58.8)	3 (75.0)	23 (63.9)

163 *Table 1: Demographics*

164

165 For categorical variables n (%) shown, for continuous variables mean (95% Confidence Interval) shown.
 166 Abbreviations: '..' = not applicable, MUST (Malnutrition Universal Screening Tool), BMI (Body Mass Index), PMS
 167 (Partial Mayo Score), HBI (Harvey Bradshaw Index), 5-ASA (5-aminosalicylic acid), Anti-TNF (anti-Tumour
 168 Necrosis Factor), Immunomodulator (azathioprine, mercaptopurine or methotrexate).

169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199

Incidence and management of hyperglycaemia


The overall global incidence of hyperglycaemia in our cohort of hospitalised IBD patients receiving IVH was 60% (56/94), with intervention for diabetes initiated in 20% (11/56) of these patients. For those without a prior diagnosis of DM, 57% (50/88) developed diabetic-range CBG (≥ 11.1 mmol/L) while 19% (17/88) and 5% (4/88) developed a CBG ≥ 14 mmol/L and ≥ 20 mmol/L, respectively. 25/50 of those with de-novo hyperglycaemia had CD, 22/50 UC, and 3/50 IBDU with a combined mean age of 44.8 years (Standard Deviation 17.4). In patients without a prior diagnosis of DM 14% (7/50) had diabetic interventions; 6/50 started an oral hypoglycaemic and 1/50 commenced insulin therapy.

All six patients with prior DM (5 CD and 1 UC) had an episode of hyperglycaemia and 4/6 recorded a CBG ≥ 20 mmol/L. 50% (3/6) were started on insulin, and 17% (1/6) commenced oral hypoglycaemic therapy.

Of the 50 admissions in patients without prior DM recording a CBG ≥ 11.1 mmol/L, 22% (11/50) were preceded directly by a course of oral steroids compared to 8% (3/38) without hyperglycaemia ($p = 0.09$, Fisher's exact test). In 60% (30/50) peak CBG occurred on day two of IVH treatment, but in 14% (7/50) of cases peak CBG was not reached until seven days after the first dose.

During index admission, 54% (30/56) of hyperglycaemic patients and 50% (19/38) of normoglycaemic patients were started on biologic therapy. Four patients underwent emergency inpatient colectomy, all of whom had recorded a hyperglycaemic episode. Mean (\pm 95% Confidence Interval) length of stay was 12.6 (\pm 3.0) days for hyperglycaemic patients and 9.1 (\pm 2.0) days for normoglycaemic patients ($p = 0.053$, t-test).

Physicians' decision making was influenced by steroid-induced hyperglycaemia, particularly in those with a persistent CBG ≥ 14 mmol/L (trigger for diabetes specialist review). Conventional post-IVH eight-week tapering course of oral prednisolone prescribing differed. Only 30% of patients with CBG ≥ 14 mmol/L received oral prednisolone without intervention (e.g. diabetic medication or rapid steroid taper) versus 58% of those with normoglycemia.




200
201 *Figure 1: Maximum recorded CBG for each admission plotted in ascending order*

202 **Predictors of hyperglycaemia**

203 Maximum CBG was positively correlated with CRP, platelet count, and HbA1c and negatively correlated with
204 haemoglobin (see correlation heat-map in supplementary data). For non-diabetic patients, the RF model was fit 500
205 times with a maximum depth of 90 trees using a random grid search method. CRP was the most critical predictor
206 identified, followed by disease duration, platelet count, admission haemoglobin and HbA1C. The final mean squared
207 error of the optimised non-diabetic patient model was 1.876.

208
209 The variables and their respective importance of contribution to the RF modelling are shown in figure 2.
210




211
212 *Figure 2: Relative variable importance for Random Forest modelling of maximum CBG (subjects with history of DM*
213 *excluded)*

214 RF models optimised by grid search will rank the relative importance of each variable against the most critical
215 variable (in this case, CRP). This provides a sense of how much each variable contributes to the predictive power of
216 the overall model. In this instance, the length of IVH usage and metabolic variables are not as crucial to predicting
217 hyperglycaemia as blood markers of inflammation.

218
219 Once the optimised RF model had been developed, blood glucose predictions were made on the holdout set using 5-
220 fold cross validation to reduce overfitting.

221
222



223
224 *Figure 3: Predicted highest CBG vs measured highest CBG using model (subjects with history of DM*
225 *excluded)*

226 Figure 3 reveals that the test-set predictions were comparable to the training set predictions. This pattern was present
227 across all folds of the cross-validation; this graph is given only as an example of the model's performance.
228

229 When the RFR model included the six patients with DM, the leading predictor of CBG elevation became HbA1c.
230 Due to high CBG elevation (≥ 20 mmol/L) in subjects with known diabetes, particularly those with evidence of
231 inadequate control by admission HbA1c, the RFR modelling shown above excluded these patients. (See
232 supplementary data) for the variable importance, correlation matrix and model with the patients with previous
233 diabetes included. Their inclusion increased the mean squared error to 2.158, which is not surprising given the
234 differing pre-admission characteristics in this sub-population.
235

236 **Additional reported side effects and metabolic instability**

237

238 32% (30/94) of episodes included a patient-reported symptom of anxiety or mood change, 11% (10/94) of poor sleep
239 and 10% (9/94) a report of appetite change. Electrolyte depletion, like hyperglycaemia, is a marker of metabolic and
240 nutritional dysregulation and was common in the whole cohort with no statistically significant differences between
241 hyperglycaemic and normoglycaemic patients. 62% (58/94) recorded a serum potassium below the lower limit of our
242 laboratory reference range (< 3.5 mmol/L), 71% (67/94) low serum magnesium (< 0.7 mmol/l) and 84% (79/94) low
243 serum phosphate (< 0.8 mmol/L). See supplementary data.
244

245 66% (37/56) of hyperglycaemic patients and 57% (21/38) of normoglycaemic patients reported weight loss in the six
246 months before admission. All patients were routinely assessed by a specialist dietitian who prescribed nutritional
247 support as indicated; 53/94 had oral nutritional supplements, 5/94 nasogastric feeding and 5/94 parenteral nutrition.
248 There was no significant difference in the proportion of hyperglycaemic versus normoglycaemic patients receiving
249 nutritional therapy.
250

251 **One-year follow-up**

252

253 There was a significant decrease in faecal calprotectin over the 12-month follow-up. For those without
254 hyperglycaemia during the acute episode, there was a trend to lower mean calprotectin at 12 months, 210 (± 707)
255 versus 738 (± 640 p=0.18 t-test). In non-diabetic patients with raised calprotectin at admission and paired results
256 35% (6/17) normalised by 12 months in those who had hyperglycaemia and 75% (9/12) normalised in those without
257 hyperglycaemia p=0.06 (Fisher's exact test). There was no significant change in HbA1c over the one-year follow-up
258 for any groups.
259

260 **DISCUSSION**

261

262 Our data demonstrate that hyperglycaemia is common in IBD patients treated with IVH. By instituting electronically
263 triggered regular CBG monitoring of IBD patients treated with IVH, we have uncovered the high prevalence of this
264 relevant complication. Our monitoring regime identified patients who required diabetic intervention or modification
265 of their treatment in response to hyperglycaemia. The void of data regarding steroid induced diabetes in IBD
266 suggests that in current practice it may often be under-recognised, and thus under-treated, potentially exposing
267 patients to the risk of complications such as increased length of stay and infection. Hyperglycaemia has also been
268 mechanistically linked to intestinal barrier dysfunction in both murine models and non-IBD human subjects.¹⁵
269 Through this mechanism, it is at least theoretically possible to link hyperglycaemia directly to intestinal
270 inflammation and IBD outcomes.¹⁶
271

272 Until now there has been no accurate prospective evidence of the extent and severity of IVH-induced
273 hyperglycaemia in IBD. A previous retrospective study of steroid side effects in elderly Crohn's disease patients
274 estimated an incidence of just 17%, but did not have systematic CBG monitoring.¹⁷ Likewise, studies of GC-treated

275 rheumatology patients report the occurrence of hyperglycaemia at 9 - 42%.¹⁸⁻²⁰ A potential explanation for the
276 higher frequency seen here is that our cohort only included hospitalised patients, who were both monitored
277 frequently and likely to have had more significant systemic inflammation. The incidence we report is similar to that
278 in a smaller study of a more elderly, heterogeneous group of hospitalised patients, prescribed GC.²¹

279
280 Machine learning techniques can be applied to clinical problems for risk prediction. We chose RF as it is a powerful
281 ensemble machine learning method for predictive modelling, known to perform better than other methods on smaller
282 datasets. Random Forests work by constructing a large number of smaller decision trees and averaging the output of
283 individual trees and are capable of capturing complex dependency patterns among multi-variate input features.

284
285 The RF model accurately predicted the degree of hyperglycaemia for those without a history of DM. Principal
286 independent determinants were admission CRP, length of disease followed by thrombocytosis and anaemia,
287 suggesting that systemic inflammatory burden and duration of IBD determines the risk of clinically significant
288 hyperglycaemia in IVH-treated IBD patients. No data of historic GC prescriptions were available so we cannot
289 speculate further on whether the relationship with disease duration is a consequence of past GC exposure or a
290 consequence of the disease process itself.

291
292 By using RF for early identification of those most at risk of significant GC-induced hyperglycaemia, alternative
293 treatment strategies can be considered, including a rapid steroid taper, early use of biologics and avoidance of oral
294 steroids in those demonstrating adequate response to biologic induction. Awareness of significant steroid-induced
295 diabetes in this cohort appeared to influence physicians' decisions with an observed reduction in follow-on
296 prescriptions for conventional steroid taper.

297
298 Although hyperglycaemia appears to resolve on stopping GC, this is not always the case. A large population-based
299 study associated previous oral GC with an increased incidence of future DM and in rheumatic diseases cumulative
300 GC dose has been shown to be a risk factor for DM.^{22,23} The IBD population, regardless of GC exposure, may be at
301 higher risk of DM. A recent Danish population-wide cohort study suggests a higher incidence of type 1 diabetes
302 amongst subjects with IBD and a Korean cohort study found IBD patients under 40 to have an increased rate of
303 incident diabetes diagnosis over five years, compared to age, sex and BMI-matched controls.^{24,25}

304
305 This study has limitations. While we note that hyperglycaemia occurred during the admission of subjects treated
306 with IVH, we do not know whether another aspect of the disease or its treatments was the principal cause. It is
307 known that de-novo hyperglycaemia may also occur in hospitalised patients independently of GC as a result of the
308 neurohormonal milieu of acute illness.²⁶ As current guidelines recommend the use of high dose GC in moderate to
309 severe acute IBD, there was no comparable cohort of patients managed without IVH treatment.³ Despite an attempt
310 to measure baseline HbA1c in all patients starting steroids, 29% did not have this checked, and 3% had neither
311 HbA1c nor CBG pre-IVH, so some cases of undiagnosed diabetes mellitus may have been missed. Future research
312 should aim to validate the model in a wider population and determine any effect of hyperglycaemia on clinical
313 outcomes, which our study was not powered to achieve.

314
315 Intravenous GC have undoubtedly saved the lives of many IBD patients. However, there is significant associated
316 morbidity, as acknowledged seven decades earlier by Truelove and Witts in their seminal work.¹ It is questionable if
317 GCs would be licensed in the regulatory framework currently applied to newer agents, given their side effect profile.
318 In the ever-evolving IBD therapeutic landscape, it may be necessary to re-evaluate the position of GCs in the
319 management of IBD. In UC, ciclosporin and infliximab are of equivalent efficacy as 'rescue' therapy for those
320 demonstrating inadequate response to IVH; whether and for how long the preceding and concomitant GC course
321 should be given for is not known.²⁷ The JAK inhibitor tofacitinib has demonstrated onset within three days in
322 moderate to severe UC and has been used effectively alongside shorter IVH courses and budesonide as induction
323 therapy in an acute severe UC case series.^{28,29}

324
325 In acute CD the evidence for the benefit of GC to induce remission is less secure.⁴ Nutritional therapies can if given
326 as exclusive enteral nutrition, be of similar efficacy as CD induction agents to oral GC. They may offer an
327 alternative treatment strategy for those in whom steroids are contraindicated.³⁰ When co-prescribed for a primary
328 nutritional indication in our cohort, nutritional therapies did not increase the risk of hyperglycaemia.

329
330 Our data supports the inclusion of CBG monitoring into standard clinical practice for IBD patients receiving IVH.
331 Machine learning identified patients with a high inflammatory disease burden and a longer disease duration as being
332 at the greatest risk of significant hyperglycaemia. Given the common complications of GCs and an enlarging
333 landscape of biological, small molecule and nutritional therapies, there is an emergent case for researching steroid-
334 free treatment strategies for acute IBD.

335
336
337

338 **ACKNOWLEDGEMENTS**

339 We would like to thank the diabetes multidisciplinary specialist team at UHS for helping to look after these patients.

340 References

- 341
- 342 1. Truelove SC, Witts L. Cortisone in ulcerative colitis. *British medical journal* 1955;
343 **2**(4947): 1041.
 - 344 2. Selinger CP, Parkes GC, Bassi A, et al. A multi-centre audit of excess steroid use in
345 1176 patients with inflammatory bowel disease. *Alimentary pharmacology & therapeutics* 2017;
346 **46**(10): 964-73.
 - 347 3. Gomollon F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on
348 the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical
349 Management. *Journal of Crohn's & colitis* 2017; **11**(1): 3-25.
 - 350 4. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory
351 bowel disease: systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**(4): 590-9;
352 quiz 600.
 - 353 5. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription.
354 *European journal of pharmacology* 2004; **500**(1-3): 51-62.
 - 355 6. Schäcke H, Döcke W-D, Asadullah K. Mechanisms involved in the side effects of
356 glucocorticoids. *Pharmacology & therapeutics* 2002; **96**(1): 23-43.
 - 357 7. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related
358 harms among adults in the United States: population based cohort study. *bmj* 2017; **357**: j1415.
 - 359 8. Conn J, Fajans S. Influence of adrenal cortical steroids on carbohydrate metabolism in
360 man. *Metabolism: clinical and experimental* 1956; **5**(2): 114-27.
 - 361 9. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in
362 hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.
363 *The Journal of clinical endocrinology and metabolism* 2012; **97**(1): 16-38.
 - 364 10. Braithwaite SS. Detection and Management of Diabetes Mellitus During Glucocorticoid
365 Therapy of Nonendocrine Disease. *Endocrine Replacement therapy in Clinical Practice*:
366 Humana Press; 2003: 254-5.
 - 367 11. Weekes CE, Elia M, Emery PW. The development, validation and reliability of a nutrition
368 screening tool based on the recommendations of the British Association for Parenteral and
369 Enteral Nutrition (BAPEN). *Clinical nutrition (Edinburgh, Scotland)* 2004; **23**(5): 1104-12.
 - 370 12. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of
371 Diabetes. *Diabetes care* 2009; **32**(7): 1327-34.
 - 372 13. Breiman L. Random forests. *Machine learning* 2001; **45**(1): 5-32.
 - 373 14. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine learning in Python.
374 *Journal of machine learning research* 2011; **12**(Oct): 2825-30.
 - 375 15. Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intestinal barrier dysfunction
376 and risk for enteric infection. *Science* 2018; **359**(6382): 1376-83.
 - 377 16. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier
378 dysfunction in inflammatory bowel diseases. *Inflammatory bowel diseases* 2009; **15**(1): 100-13.
 - 379 17. Akerkar GA, Peppercorn MA, Hamel MB, Parker RA. Corticosteroid-associated
380 complications in elderly Crohn's disease patients. *American Journal of Gastroenterology* 1997;
381 **92**(3).
 - 382 18. Ha YJ, Lee K, Jung S, Lee S, Lee S, Park Y. Glucocorticoid-induced diabetes mellitus in
383 patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy.
384 *Lupus* 2011; **20**(10): 1027-34.
 - 385 19. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of
386 hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. *Scottish medical*
387 *journal* 2004; **49**(4): 139-41.

- 388 20. Ito S, Ogishima H, Kondo Y, et al. Early diagnosis and treatment of steroid-induced
389 diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases.
390 *Modern rheumatology* 2014; **24**(1): 52-9.
- 391 21. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of
392 corticosteroid-related hyperglycemia in hospitalized patients. *Endocr Pract* 2006; **12**(4): 358-62.
- 393 22. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed
394 glucocorticoids in a large population. *Diabetes care* 2006; **29**(12): 2728-9.
- 395 23. Movahedi M, Beauchamp M-E, Abrahamowicz M, et al. Risk of Incident Diabetes
396 Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients
397 With Rheumatoid Arthritis. *Arthritis & Rheumatology* 2016; **68**(5): 1089-98.
- 398 24. Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory
399 bowel disease have increased risk of autoimmune and inflammatory diseases. *World journal of*
400 *gastroenterology* 2017; **23**(33): 6137-46.
- 401 25. Kang EA, Han K, Chun J, et al. Increased Risk of Diabetes in Inflammatory Bowel
402 Disease Patients: A Nationwide Population-based Study in Korea. *J Clin Med* 2019; **8**(3): 343.
- 403 26. Dungan KM, Braithwaite SS, Preiser J-C. Stress hyperglycaemia. *The Lancet* 2009;
404 **373**(9677): 1798-807.
- 405 27. Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant
406 acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic
407 randomised trial. *The Lancet Gastroenterology & Hepatology* 2016; **1**(1): 15-24.
- 408 28. Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces
409 symptoms within 3 days for patients with ulcerative colitis. *Clinical Gastroenterology and*
410 *Hepatology* 2019; **17**(1): 139-47.
- 411 29. Berinstein JA, Steiner CA, Regal RE, et al. Efficacy of Induction Therapy With High-
412 Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. *Clinical Gastroenterology*
413 *and Hepatology* 2019; **17**(5): 988-90.e1.
- 414 30. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional
415 therapy for induction of remission in Crohn's disease. *Cochrane Database of Systematic*
416 *Reviews* 2018; (4).
- 417

418 **SUPPLEMENTARY DATA**

419

420 **Input features for RF model:**

421 MUST score, weight loss during the past six months (<5%, 5-10%, >10%), diagnosis (CD, UC, IBDU), time since
422 diagnosis, admission faecal calprotectin and admission measurements of serum haemoglobin, platelets, magnesium,
423 phosphate, potassium and CRP.

424

425 **GridSearch optimised parameters of the RF model:**

- 426 • For patients with no history of DM: 'n_estimators': 733, 'min_samples_split': 10, 'min_samples_leaf': 4,
427 'max_features': 'sqrt', 'max_depth': 90, 'bootstrap': True
- 428 • For all patients regardless of DM history: 'n_estimators': 3400, 'min_samples_split': 2, 'min_samples_leaf':
429 4, 'max_features': 'sqrt', 'max_depth': 80, 'bootstrap': False

430


431

432


433

434


435 *Supplementary figure 1: Correlation heat map of Random Forest parameters (subjects with history of DM excluded)*



438 *Supplementary figure 2: Predicted highest CBG vs measured highest CBG (all patients)*




439
440 *Supplementary figure 3: Variable importance for Random Forest modelling (all patients)*




441
442
443

444 *Supplementary figure 4: Correlation heat map of Random Forest parameters (all patients)*



449 *Supplementary figure 5: Lowest recorded electrolyte measurements (all patients) stratified by hyperglycaemia*
450 *(maximum capillary blood glucose (CBG) \geq 11mmol/L) or normoglycaemia (maximum CBG < 11mmol/L).*


451



452
453

454 *Supplementary figure 6: Highest recorded blood glucose stratified by nutritional supplements given (all patients)*

455 NG = Nasogastric tube feeding, Oral = Oral nutritional supplements, TPN = total parenteral nutrition



456